AUTHORS
Robert F Sidonio, MD, MSc, Michelle Sholzberg, MD2, Kristen Jaworski, PhD3, Jacob S. Lai, PhD4, Josie Gauthier5, Lauren Bylsma, MPH6, Naomi Sacks, PhD7, Meghan E Mitchell, MPH8, Nicole M. Engel-Nitz, PhD, MS9, Angela Weyand, MD10
AFFILIATIONS
1 Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University, Atlanta, Georgia, United States
2 Hematology-Oncology Clinical Research Group, Division of Hematology, St. Michael's Hospital and University of Toronto, Toronto, Ontario, Canada
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 BlueRidge Life Sciences, Katy, Texas, United States
6 BlueRidge Life Sciences, Katy, Texas, United States
7 BlueRidge Life Sciences, Katy, Texas, United States
8 BlueRidge Life Sciences, Katy, Texas, United States
9 Value and Evidence Solutions, Optum, Eden Prairie, Minnesota, United States
10 Department of Pediatrics and Communicable Diseases, Division of Pediatric Hematology and Oncology, University of Michigan, Ann Arbor, Michigan, United States
ABSTRACT
Introduction: Von Willebrand disease (VWD) is an inherited bleeding disorder caused by quantitative or qualitative defects in von Willebrand factor (VWF), resulting in impaired hemostasis. The bleeding phenotype is heterogeneous and includes heavy menstrual bleeding, epistaxis, gastrointestinal (GI), muscle, joint, procedural, and traumatic bleeding. Although some bleeding events are severe and require hospitalization, others occur at lower intensity on a daily or monthly basis. Recurrent blood loss may cumulatively deplete iron stores, impair erythropoiesis, and lead to iron-deficiency anemia, which is associated with fatigue, reduced physical function, and diminished quality of life. Despite frequent bleeding in VWD, the prevalence and clinical burden of anemia in this population are not well described. The objective of this analysis was to describe real-world disease impact on patients with VWD and anemia.
Methods: This retrospective population-based study used administrative claims and linked laboratory data from commercial and Medicare Advantage enrollees in the Optum Research Database between Jan 2007 and Oct 2023. Patients were identified as having VWD if they met ≥1 of the following criteria: 1) ≥2 claims with an ICD-9/10 code for VWD (286.4, D68.0x) at least 30 d apart; 2) any VWD-specific treatment; or 3) ≥1 laboratory result with VWF antigen (VWF:Ag) or ristocetin cofactor (VWF:RCo) of <50 IU/dL. Index date was the earliest date on which any of these criteria were met. Eligible patients had ≥6 mo of continuous health insurance coverage before and ≥30 d after index date, unless death occurred within the post-index period. The subgroup of patients with anemia (ICD-9/10-CM codes categorized as “anemia” or “iron-deficiency anemia”) was compared with those without anemia and a control group without VWD. Assessments included disease burden (eg, bleeding events), treatment burden (eg, blood transfusions), and healthcare resource utilization (HCRU) during a 12-mo period spanning 6 mo before and 6 mo after the index date.
Results: A total of 9882 patients in the database met criteria for VWD diagnosis; of these, 2509 (25.4%) had evidence of anemia during the 6-mo baseline period. Mean age was higher (45.8 vs 36.3 y), and there was a higher proportion of females (79.7% vs 70.6%) in patients with VWD and anemia than those without anemia. Patients with VWD and anemia had a significantly higher comorbidity burden compared with those without anemia (mean Charlson Comorbidity Index score, 0.9 vs 0.4), including prevalence of depression, anxiety, obesity/overweight, hypertension, diabetes, thromboembolic events, arthralgia, peptic ulcer disease, and chronic kidney disease (all P<0.001). Among 9104 patients with VWD observable through the 6-mo follow-up period (n=2389 with anemia), significantly more of those with anemia versus without experienced bleeding events of heavy menstrual bleeding (34.8% vs 20.4% of females), GI bleeding (11.1% vs 3.1%), any hemorrhage (4.9% vs 2.9%), and blood in urine (4.0% vs 2.5%; all P<0.001). Compared to people without VWD (n=85,546), heavy menstrual bleeding and GI bleeding were 15- and 11-fold more prevalent, respectively, in patients with VWD and anemia, supporting recurrent bleeding as a potential contributor to anemia. More patients with VWD and anemia required transfusion (22.9%) versus those without anemia (8.4%). HCRU was higher in patients with VWD and anemia versus those without anemia, including mean monthly number of inpatient admissions (2.5X), emergency department visits (1.7X), ambulatory visits (1.6X), and filled pharmacy prescriptions (1.6X).
Conclusion: In this real-world analysis using a US claims dataset, anemia was present in approximately 1 in 4 patients with VWD and was associated with higher rates of comorbidities, bleeding events, transfusion use, and HCRU than patients with VWD without anemia. Though temporality cannot be inferred as bleeding and anemia were assessed in the same observation window, the higher prevalence of bleeding in patients with VWD and anemia suggests that recurrent mucosal blood loss may be a contributor to anemia, underscoring the clinically meaningful impact of frequent bleeding. With guidelines recommending long-term prophylaxis for patients with severe and frequent bleeds, identification of patients with VWD at risk for anemia could help optimize treatment strategies to reduce this disease burden, including consideration of prophylaxis.
DISCLOSURES
Robert F Sidonio, MD, MSc: Sobi/Sanofi - Honoraria; Takeda - Research Funding; Octapharma - Research Funding; LFB/Hema Biologics - Research Funding; Bayer - Consultancy (Includes expert testimony); Guardian Therapeutics - Consultancy (Includes expert testimony); Novo Nordisk - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Genentech/Roche - Consultancy (Includes expert testimony); BioMarin - Consultancy (Includes expert testimony); LFB/Hema Biologics - Consultancy (Includes expert testimony); Sobi/Sanofi - Consultancy (Includes expert testimony); Octapharma - Consultancy (Includes expert testimony); Vega - Consultancy (Includes expert testimony)